Comparison of Molecular Responses between e14a2 and e13a2 BCR-ABL1 Transcripts in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Front-Line Second Generation Tyrosine Kinase Inhibitors: Taiwan CML Study

被引：0
|
作者：
Su, Yi-Jiun
Kuo, Ming-Chung
Teng, Chieh-Lin
Chen, Tsai-Yun
Ma, Ming-Chun
Hsiao, Pei-Ching
Wang, Ming-Chung
Lin, Tung-Huei
Hwang, Wen-Li
Chen, Chih-Cheng
Yang, Youngsen
Pei, Sung-Nan
Huang, Yen-Min
Li, Sin-Syue
Lee, Ming-Yang
Cheng, Hung-I
Shih, Lee-Yung
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1603
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Comparison of molecular responses and outcomes between BCR::ABL1 e14a2 and e13a2 transcripts in chronic myeloid leukemia
    Su, Yi-Jiun
    Kuo, Ming-Chung
    Chen, Tsai-Yun
    Wang, Ming-Chung
    Yang, Youngsen
    Ma, Ming-Chun
    Lin, Tung-Liang
    Lin, Tung-Huei
    Chang, Hung
    Teng, Chieh-Lin Jerry
    Hsiao, Pei-Ching
    Chen, Chih-Cheng
    Wang, Po-Nan
    Shih, Lee-Yung
    CANCER SCIENCE, 2022, 113 (10) : 3518 - 3527
  • [2] Response to Imatinib in e13a2 Versus e14a2 BCR-ABL Fusion Transcripts in Chronic Myeloid Leukemia Saudi Patients
    Elbjeirami, Wafa M.
    Alabdulwahab, Amal S.
    Elsayed, Hussein G.
    Abdelghaffer, Nermeen Adel
    Elnagdi, Noha
    Al-Jedani, Hanadi
    Abd Allatif, Nahla
    Al Shaikh, Abdulaziz
    Al-Allaf, Faisal
    BLOOD, 2016, 128 (22)
  • [3] No Influence of BCR-ABL1 Transcript Types e13a2 and e14a2 on MR4.5 in Patients with Chronic Myeloid Leukemia Treated with Nilotinib Frontline
    Genthon, Alexis
    Nicolini, Franck Emmanuel
    Berger, Marc G.
    Saugues, Sandrine
    Janel, Alexandre
    Guyotat, Denis
    Hayette, Sandrine
    Campos, Lydia
    Flandrin-Gresta, Pascale
    BLOOD, 2017, 130
  • [4] Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib
    Hanfstein, Benjamin
    Lauseker, Michael
    Hehlmann, Ruediger
    Saussele, Susanne
    Erben, Philipp
    Dietz, Christian
    Fabarius, Alice
    Proetel, Ulrike
    Schnittger, Susanne
    Haferlach, Claudia
    Krause, Stefan W.
    Schubert, Joerg
    Einsele, Hermann
    Haenel, Mathias
    Dengler, Jolanta
    Falge, Christiane
    Kanz, Lothar
    Neubauer, Andreas
    Kneba, Michael
    Stegelmann, Frank
    Pfreundschuh, Michael
    Waller, Cornelius F.
    Spiekermann, Karsten
    Baerlocher, Gabriela M.
    Pfirrmann, Markus
    Hasford, Joerg
    Hofmann, Wolf-Karsten
    Hochhaus, Andreas
    Mueller, Martin C.
    HAEMATOLOGICA, 2014, 99 (09) : 1441 - 1447
  • [5] No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib
    Pfirrmann, Markus
    Evtimova, Dobromira
    Saussele, Susanne
    Castagnetti, Fausto
    Cervantes, Francisco
    Janssen, Jeroen
    Hoffmann, Verena S.
    Gugliotta, Gabriele
    Hehlmann, Ruediger
    Hochhaus, Andreas
    Hasford, Joerg
    Baccarani, Michele
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2017, 143 (05) : 843 - 850
  • [6] No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib
    Markus Pfirrmann
    Dobromira Evtimova
    Susanne Saussele
    Fausto Castagnetti
    Francisco Cervantes
    Jeroen Janssen
    Verena S. Hoffmann
    Gabriele Gugliotta
    Rüdiger Hehlmann
    Andreas Hochhaus
    Joerg Hasford
    Michele Baccarani
    Journal of Cancer Research and Clinical Oncology, 2017, 143 : 843 - 850
  • [7] Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript
    Lucas, Claire M.
    Harris, Robert J.
    Giannoudis, Athina
    Davies, Andrea
    Knight, Katy
    Watmough, Sarah J.
    Wang, Lihui
    Clark, Richard E.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (10): : 1362 - 1367
  • [8] Favorable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib
    Mulas, Olga
    Caocci, Giovanni
    Annunziata, Mario
    Martino, Bruno
    Luciano, Luigiana
    Castagnetti, Fausto
    Pregno, Patrizia
    Galimberti, Sara
    Albano, Francesco
    Orlandi, Ester M.
    Sgherza, Nicola
    Iurlo, Alessandra
    Bonifacio, Massimiliano
    Binotto, Gianni
    Gozzini, Antonella
    Bocchia, Monica
    Abruzzese, Elisabetta
    Fozza, Claudio
    Simula, Maria P.
    De Gregorio, Fiorenza
    Gugliotta, Gabriele
    Pirillo, Francesca
    Barate, Claudia
    Attolico, Imma
    Elena, Chiara
    Cattaneo, Daniele
    Scaffidi, Luigi
    Sicuranza, Anna
    Trawinska, Malgorzata M.
    Scalzulli, Emilia
    Foa, Robin
    Breccia, Massimo
    La Nasa, Giorgio
    HEMATOLOGICAL ONCOLOGY, 2020, 38 (04) : 607 - 610
  • [9] Molecular response to imatinib is achieved faster in chronic myeloid leukemia (CML) patients harboring the e14a2 BCR-ABL fusion transcript compared to those harboring e13a2
    Hanfstein, B.
    Erben, P.
    Agrawal, M.
    Schnittger, S.
    Ernst, T.
    Schenk, T.
    Hofmann, W-K
    Hehlmann, R.
    Hochhaus, A.
    Mueller, M. C.
    ONKOLOGIE, 2010, 33 : 145 - 145
  • [10] Distinct Characteristics of e13a2 versus e14a2 BCR-ABL Chronic Myeloid Leukemia under Upfront Treatment with Imatinib - an Analysis of the German CML Study IV
    Hanfstein, Benjamin
    Erben, Philipp
    Saussele, Susanne
    Lauseker, Michael
    Proetel, Ulrike
    Haag, Sven
    Schnittger, Susanne
    Haferlach, Claudia
    Kolb, Hans-Jochem
    Krause, Stefan W.
    Nerl, Christoph
    Heim, Dominik
    Baerlocher, Gabriela M.
    Schubert, Joerg E. A.
    Einsele, Hermann
    Haenel, Mathias
    Dengler, Jolanta
    Falge, Christiane
    Kanz, Lothar
    Neubauer, Andreas
    Kneba, Michael
    Stegelmann, Frank
    Pfreundschuh, Michael
    Waller, Cornelius F.
    Pfirrmann, Markus
    Hasford, Joerg
    Hofmann, Wolf-Karsten
    Hehlmann, Ruediger
    Hochhaus, Andreas
    Mueller, Martin C.
    BLOOD, 2011, 118 (21) : 1612 - 1612
12345